A multiple dose study to evaluate the pharmacokinetics of an acoramidis (AG10) modified release tablet formulation in healthy subjects
Latest Information Update: 22 Nov 2023
At a glance
- Drugs Acoramidis (Primary)
- Indications Transthyretin-related hereditary amyloidosis
- Focus Pharmacokinetics
- Sponsors Eidos Therapeutics
- 31 Aug 2022 New trial record